Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial
An experimental immune-boosting antibody combined with chemotherapy helped advanced lung cancer patients previously resistant to immunotherapy, with early response prediction.
Phase II trial of cadonilimab, a PD-1/CTLA-4 bispecific antibody, plus platinum doublet chemotherapy produced 66% ORR and 100% disease control in PD-L1-negative NSCLC — a major immunotherapy-resistant subgroup — with an integrated cfDNA methylation biomarker providing early response prediction. Results published in Nature Communications warrant confirmatory phase III evaluation.
What the study was
- Study design
- Phase II single-arm clinical trial (ChiCTR2300071681)
- Population
- PD-L1-negative advanced NSCLC patients
- Sample size
- 50
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Nature Communications
Why it surfaced
PD-L1-neg NSCLC is one of the largest unmet immunotherapy subpopulations; phase II Nat Commun showing 66% ORR with PD-1/CTLA-4 bispecific + chemo; cfDNA methylation early-response biomarker adds dual innovation value.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.